1. Home
  2. RDI vs PLUR Comparison

RDI vs PLUR Comparison

Compare RDI & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

N/A

Current Price

$1.25

Market Cap

23.4M

ML Signal

N/A

Logo Pluri Inc.

PLUR

Pluri Inc.

HOLD

Current Price

$1.67

Market Cap

25.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
PLUR
Founded
1937
2001
Country
United States
Israel
Employees
2005
N/A
Industry
Movies/Entertainment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
25.5M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
RDI
PLUR
Price
$1.25
$1.67
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
15.1K
31.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
$16.25
$97.38
Revenue Next Year
$4.04
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$0.94
$1.78
52 Week High
$1.65
$5.68

Technical Indicators

Market Signals
Indicator
RDI
PLUR
Relative Strength Index (RSI) 46.94 27.38
Support Level $0.99 N/A
Resistance Level $1.26 $2.53
Average True Range (ATR) 0.06 0.13
MACD -0.01 -0.01
Stochastic Oscillator 5.01 15.00

Price Performance

Historical Comparison
RDI
PLUR

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: